Imperial College London

DrAndrewInnes

Faculty of MedicineDepartment of Immunology and Inflammation

Honorary Clinical Senior Lecturer
 
 
 
//

Contact

 

+44 (0)20 3313 4017a.innes

 
 
//

Location

 

Commonwealth BuildingHammersmith Campus

//

Summary

 

Summary

NIHR Academic Clinical Lecturer in Haematology 

Selected Publications

Journal Articles

Innes A, Sun B, Wagner V, et al., 2021, XPO7 is a tumor suppressor regulating p21CIP1-dependent senescence, Genes & Development, Vol:35, ISSN:0890-9369, Pages:379-391

Salisbury RA, Curto-Garcia N, O’Sullivan J, et al., 2021, Results of a national UK physician reported survey of COVID-19 infection in patients with a myeloproliferative neoplasm, Leukemia, Vol:35, ISSN:0887-6924, Pages:2424-2430

Cuartero S, Innes AJ, Merkenschlager M, 2019, Towards a better understanding of cohesin mutations in AML, Frontiers in Oncology, Vol:9, ISSN:2234-943X

Innes A, Wooley P, Szydlo R, et al., 2019, Complete remission with incomplete count recovery (CRi) prior to allogeneic HCT for acute myeloid leukaemia is associated with a high non-relapse mortality., Leukemia, Vol:34, ISSN:1476-5551, Pages:667-670

Gupta RK, Abdul-Jawad S, McCoy LE, et al., 2019, HIV-1 remission following CCR5Δ32/Δ32 haematopoietic stem-cell transplantation, Nature, Vol:568, ISSN:0028-0836, Pages:244-248

Innes AJ, Gil J, 2019, IMR90 ER:RAS: A cell model of oncogene-induced senescence, Methods in Molecular Biology, Vol:1896, ISSN:1940-6029, Pages:83-92

Innes AJ, Mullish BH, Fernando F, et al., 2017, Faecal microbiota transplant: a novel biological approach to extensively drug-resistant organism-related non-relapse mortality., Bone Marrow Transplantation, Vol:52, ISSN:1476-5365, Pages:1452-1454

Innes AJ, Milojkovic D, Apperley JF, 2016, Allogeneic transplantation for CML in the TKI era: striking the right balance, Nature Reviews Clinical Oncology, Vol:13, ISSN:1759-4774, Pages:79-91

Herranz N, Gallage S, Mellone M, et al., 2015, mTOR regulates MAPKAPK2 translation to control the senescence-associated secretory phenotype, Nature Cell Biology, Vol:17, ISSN:1476-4679, Pages:1205-1217

Innes AJ, Beattie R, Sergeant R, et al., 2013, Escalating-dose HLA-mismatched DLI is safe for the treatment of leukaemia relapse following alemtuzumab-based myeloablative allo-SCT, Bone Marrow Transplantation, Vol:48, ISSN:0268-3369, Pages:1324-1328

More Publications